•Impact of Inflammatory Bowel Disease on Outcomes After Coronary Interventions: A Systematic Review and Meta-Analysis
•Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease
•Recent developments in the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases
•Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort
•Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease
